At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 69 enrolled
Drug / intervention
Etanercept +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety, Population Pharmacokinetics, and Efficacy of Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein (TNFR:Fc) in Children With Juvenile Rheumatoid Arthritis
In Brief
A Phase 3 clinical trial evaluating Etanercept and Placebo for Juvenile Rheumatoid Arthritis. Completed, enrolled 69 participants.
Detailed Summary
The primary objective of this study was to determine the efficacy of etanercept in children with polyarticular course JRA.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsJuvenile Rheumatoid Arthritis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 1997
Primary CompletionJul 1998
First PostedDec 2018
TodayJul 2026
First PostedDec 19, 2018
Enrollment StartMay 1, 1997
Primary CompletionJul 8, 1998
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 7.5 years ago
Interventions
Etanerceptdrug
Administered twice weekly by subcutaneous injection
Placebodrug
Administered twice weekly by subcutaneous injection